Key clinical point: A post hoc analysis suggests lenalidomide maintenance therapy does not reduce health-related quality of life (HRQoL) in patients with diffuse large B-cell lymphoma (DLBCL).
Major finding: Among patients who received lenalidomide, there were no significant changes observed in 3 major HRQoL domains: fatigue, physical functioning, and global health status).
Study details: A subpopulation analysis of data for 457 patients from the phase 3 REMARC trial.
Disclosures: The study was funded by Celgene. The authors reported financial affiliations with Celgene and other companies.
Thieblemont C et al. Br J Haematol. 2019 Nov 8. doi: 10.1111/bjh.16300.